[go: nahoru, domu]
Jump to content

The Medical Letter on Drugs and Therapeutics

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by WLU (talk | contribs) at 14:17, 29 June 2010 (→‎Editorial Process: rewrite, build flowchart into citation). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

The Medical Letter on Drugs and Therapeutics
DisciplinePublication
LanguageEnglish, French, Italian, Japanese, Spanish and a Canadian adapted version, written in English
Publication details
Historyfirst published 1959
Publisher
Standard abbreviations
ISO 4Med Lett Drugs Ther
Indexing
ISSN1523-2859
Links

The Medical Letter on Drugs and Therapeutics, commonly referred to as The Medical Letter, is a scientific journal that promotes itself as providing independent, evaluations of drugs on the basis of novel information. The Medical Letter is well known as the "Gold Standard", for new drug review within the medical community for over five decades.[citation needed]

The Medical Letter has a print and electronic circulation of well over 450,000 subscribers in 125 countries worldwide.

Published biweekly (26 issues/year), the newsletter is available in several languages: English (US and Canadian editions), French (Canadian and European editions), Italian, Japanese, and Spanish.The Medical Letter is also available as an electronic site license for institutions such as medical schools, hospitals and group practices.

The Medical Letter is published by The Medical Letter, Inc., which also publishes the monthly Treatment Guidelines from The Medical Letter.

Editorial process

Articles for The Medical Letter are drafted by either an editor or external consultant using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of clinical trials. A preliminary draft is circulated to every member of the advisory board and 10-20 other investigators with relevant clinical or experimental experience with the article's topic. Drafts are also provided to the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC), all first authors of articles cited in the text and to the pharmaceutical companies that manufacture the drug, or similar compounds. The evaluation of each drug includes a discussion of its efficacy, side effects, and a comparison with older, more established agents. The final version of the paper includes comments from the reviewers and the final version is checked and edited to make sure it is both accurate and readable.[1]

See also

  1. ^ "Flowchart of the editorial process" (pdf). The Medical Letter, Inc. Retrieved 2010-06-29.
Retrieved from "https://en.wikipedia.org/w/index.php?title=The_Medical_Letter_on_Drugs_and_Therapeutics&oldid=370793644"